We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Advanced Mass Spectrometry Could Provide Microscopic Clues to Beating Deadly Brain Tumors

By LabMedica International staff writers
Posted on 01 Nov 2022

Glioblastoma is one of the most difficult cancers, let alone diseases, to treat. More...

The brain tumor presents a median survival rate of just 12 to 15 months. The cancer is especially hard to beat, since it presents so heterogeneously – with different tumor cell subtypes within the same tumor, which can all respond differently to therapy. The cancer also has a tendency to create aberrant small blood vessel networks quickly, helping it spread quickly – and making it particularly hard to defeat through traditional treatment pathways. Now, scientists have discovered that a critical new pathway to treating glioblastoma might be found in the complex diversity within the tumor tissue.

A team of scientists at the Hackensack Meridian Center for Discovery and Innovation (CDI, Nutley, NJ, USA) deeply analyzed tumor tissue using an advanced mass spectrometry with special focus on lipids, a class of molecules that includes fats. The scientists assessed five human samples of brain tumor tissue. The team looked at a series of different lipids, in different sections of the tumor and the surrounding environment, and found a series of possible treatment candidates.

“Lipid ions presented here lay the foundation for future studies that are required to understand their interconnecting signaling pathways in relation to cell function, tumor progression, and resistance to therapy,” according to the paper. “Understanding their functional relevance is essential for the identification of new therapeutics based on lipid pathway targets.”

“In conclusion, high resolution MALDI MSI identified a number of lipids that differentiate tumor and endothelial cell subpopulations within human glioblastoma samples,” the authors write. “The heterogenous distributions… within these cell population further highlight the complexity of the glioblastoma TME.”

The scientists hypothesize that a multi-pronged approach may fare best against the stubborn cancer.

“Targeting several of these lipids and their signaling pathways simultaneously, however, may improve clinical outcome,” they write.

Related Links:
CDI


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
New
Portable POCT Blood Gas Analyzer
BD100
New
Gastrointestinal Panel
Xpert® GI Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.